(2004) Death rate statistics of Korea,

(2004) Chemotherapy in stage-IV NSCLC,

(1999) Molecular pathogenesis of lung cancer,

(2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline:update 2003,

(2005) Carboplatin versus cisplatin in lung cancer,

(2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer,

(2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer,

(2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer:a meta-analysis of survival outcomes,

(2005) Web based clinical trial manager 2005,

(2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy,

(2006) Small Cell Lung Cancer (PDQ？？) Treatment 2006,

(2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer,

(2004) Novel therapies for advanced non-small cell lung cancer-1,

(2004) Novel therapies for advanced non-small cell lung cancer-2,

(2002) Novel targets for lung cancer therapy:part I,

(2002) Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer,

(2003) Dermatologic side effects associated with gefitinib therapy:clinical experience and management,

(2003) Efficacy of gefitinib an inhibitor of the epidermal growth factor receptor tyrosine kinase in symptomatic patients with non-small cell lung cancer,

(2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial),

(2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer,

(2004) Gefitinib(ZD1839)monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer,

(2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan,

(2005) Predictors of the response to gefitinib in refractory non-small cell lung cancer,

(2003) Gefitinib in pretreated non-small-cell lung cancer(NSCLC)analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC,

(2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer,

(2005) Chasing mutations in the epidermal growth factor in lung cancer,

(2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways,

(2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,

(2004) EGF receptor gene mutations are common in lung cancers from and are associated with sensitivity of tumors to gefitinib and erlotinib,

(2004) EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy,

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib,

(2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain,

(2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib,

(2005) Irreversible inhibitorsof the EGF receptor may circumvent acquired resistance to gefitinib,

(2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib,

ISEL: a phase III in patients with advanced non-small -cell lung cancer who had received one or two prior chemotherapy regimens,

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, ,

(2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839(Iressa)an inhibitor of EGFR tyrosine kinase,

(2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839(Iressa)an epidermal growth factor receptor-selective tyrosine kinase inhibitor,

(2003) Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer,

(2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase III trial-INTACT 1,

(2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer:a phase III trial--INTACT 2,

(2004) United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. ,

(2003) Epidermal growth factor receptor targeted therapy by ZD 1839 in patients with brain metastases from non-small cell lung cancer,

Gefitinib is also active for carcinomatous meningitis in NSCLC,

(zd18392005) Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient,

(2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinomaafter response to gefitinib,

(2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer,

(2005) Erlotinib in previously treated non-small-cell lung cancer,

(2005) Erlotinib in lung cancer:molecular and clinical predictors of outcome,

(2001) The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux,

(1996) Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145,

(1999) Antitumor activity of sequential treatment with topotecanand anti-epidermal growth factor receptor monoclonal antibody C225,

(2004) Cetuximab in advanced non-small cell lung cancer,

(2004) Preclinical and clinical evaluations of ABX-EGF,a fully human anti-epidermal growth factor receptor antibody,

(2001) c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis,

(2001) Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents,

(2004) Trastuzumab in the treatment of advanced non-small-cell lung cancer,

(2004) Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease,

(2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer,

(2004) Lung cancer:intragenic ERBB2 kinase mutations in tumours,

(2002) Inhibition of KIT tyrosine kinase activity:a novel molecular approach to the treatment of KIT-positive malignancies,

(2002) Regulation of cellular proliferation,cytoskeletal function,and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells,

(2001) Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells,

(2003) Phase II study of imatinib in patients with small cell lung cancer,

(2003) Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer,

(2003) A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combinationwith gemcitabine and cisplatin in patients with advanced cancer,

(2001) Phase I Trial of ISIS 5132,an antisense oligonucleotide inhibitor of c-raf-1,administered by 24-hour weekly infusion to patients with advanced cancer,

(1994) Regulation of protein kinase C and role in cancer biology,

(2000) The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth,mitotic entry,and blood flow,

(2003) A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer,

(2004) A phase I/II study of LY900003,an antisense inhibitor of protein kinase C-alpha,in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer,

(2001) Aphase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer,

(2000) Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1,

(2000) Exisulind induction of apoptosis involves guanosine 3',

(2004) A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors,

(2002) Novel targets for lung cancer therapy:part II,

(1999) Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers,

(2003) Current status of gene therapy for lung cancer and head and neck cancer, Clin Cancer Res

(1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer,

(2001) Clinical evaluation of adenoviral-mediated p53 gene transfer:review of INGN 201 studies,

(1998) A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer,

(2001) Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer:results of a multicenter phase II study,

(2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines,

(1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide,doxorubicin and cisplatin on small-cell lung cancer cell lines,

(1997) Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence,

(2002) A pilot trial of G3139,a bcl-2 antisense oligonucleotide,and paclitaxel in patients with chemorefractory small-cell lung cancer,

(2004) Phase I study of G3139,a bcl-2 antisense oligonucleotide,combined with carboplatin and etoposide in patients with small-cell lung cancer,

(2000) Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells,

(2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer,

(2005) Bevacizumab and chemotherapy improves survival in NSCLC,

(2004) Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer,

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer,

(1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers,specifically in adenocarcinomas,

(2003) Celecoxib,a selective cyclo-oxygenase-2 inhibitor,enhances the response to preoperative paclitaxel and carboplatin in early-stage non- small-cell lung cancer,

(2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors,

(2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily,

(2002) Safety and pharmacokinetic effects of TNP-470 combined with paclitaxel in patients with solid tumors evidence for activity in non-small-cell lung cancer,